Compound ID | 91

Update compound information

Ceftobiprole (active moiety of ceftobiprole medocaril)

Synonym(s): Zevtera

Class: Beta-lactam (cephalosporin)

Spectrum of activity: Gram-positive  &  Gram-negative
Details of activity: Basilea's broad-spectrum antibiotic ceftobiprole gained regulatory approval in thirteen European countries for the treatment of community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP) in adults, excluding ventilator-associated pneumonia (VAP). The drug was launched in Germany in the fourth quarter of 2014 with further European launches planned for 2015. Not approved by the FDA, so no US launch as of yet.
Institute where first reported: Basilea Pharmaceutica, Switzerland
Year first mentioned: 2002
Highest developmental phase: Approved by FDA in 2024
Development status: Approved
Chemical structure(s):
Click here for structure editor
Molecular weight: 534.57
Iso. SMILES: C1CNC[C@@H]1N2CC/C(=C\C3=C(N4[C@@H]([C@@H](C4=O)NC(=O)/C(=N\O)/C5=NSC(=N5)N)SC3)C(=O)O)/C2=O
InChI Key: VOAZJEPQLGBXGO-SDAWRPRTSA-N
Can. SMILES: C1CNC[C@@H]1N2CC/C(=C\C3=C(C(=O)O)N4C(=O)[C@H]([C@H]4SC3)NC(=O)/C(=N\O)/C5=NSC(=N5)N)/C2=O
InChI: InChI=1S/C20H22N8O6S2/c21-20-24-14(26-36-20)11(25-34)15(29)23-12-17(31)28-13(19(32)33)9(7-35-18(12)28)5-8-2-4-27(16(8)30)10-1-3-22-6-10/h5,10,12,18,22,34H,1-4,6-7H2,(H,23,29)(H,32,33)(H2,21,24,26)/b8-5+,25-11-/t10-,12-,18-/m1/s1
External links:
PubChem link: https://pubchem.ncbi.nlm.nih.gov/compound/135413542
Guide to Pharmacology: ceftobiprole
Citations:
  • https://www.basilea.com/fileadmin/user_upload/pressreleases/1803157-en-01-201904112_Basilea_Press_release_ECCMID_EN.pdf?v=1565587522
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC126986/
  • https://www.tandfonline.com/doi/pdf/10.1080/14787210.2019.1667229
  • https://www.basilea.com/news/news/basilea-announces-positive-results-of-phase-3-target-study-with-antibiotic-ceftobiprole-in-the-treatment-of-acute-bacterial-skin-and-skin-structure-infections-absssi?type=1546938654
    • Patent: CN103275104B

    AntibioticDB is supported by GARDP.

    If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions

    The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.